Eli Lilly (Lilly) has agreed to make a $10m upfront payment for full worldwide rights to San Diego-based Organovo Holdings’ farnesoid X receptor (FXR) agonist programme, aimed at treating inflammatory ...

The farnesoid X receptor (FXR) is a bile acid nuclear receptor that plays a crucial role in regulating bile acid and sterol metabolism.

are nuclear receptors mainly expressed in the liver and intestine. FXR agonists are synthetic compounds thought to hold potential across several gastrointestinal (GI) diseases. However ...

xenobiotic compounds and microbial byproducts can maintain critical gut immunity by inducing antimicrobial gene expression. FXR: Farnesoid X receptor; VDR: Vitamin D receptor; RXR: Retinoid X ...

Eli Lilly (NYSE: LLY) stock defied today's market downturn, rising 2.6% through 11:15 a.m. ET on the back of two positive press releases. In one, Lilly announced plans to acquire the farnesoid X ...

The Swiss pharma said it is to begin a phase IIb trial of one of its Farnesoid X receptor (FXR) agonists in combination with Allergan’s cenicriviroc in NASH. A group of around half a dozen ...

Ready to save your liver? Transcription factors are paving the way for metabolic dysfunction-associated fatty liver disease ...

Our lab identified that excessive copper concentrations decreased metabolic nuclear receptor activity (FXR - farnesoid X receptor, HNF4a – hepatocyte nuclear factor, and LRH-1 – liver receptor homolog ...

Metabolic dysfunction-associated fatty liver disease (MAFLD) has become a growing global health concern, affecting millions ...